

Spop promotes skeletal development and homeostasis by positively regulating *Ihh* signaling

 Hongchen Cai^{a,b,c} and Aimin Liu^{a,b,c,1}

^aDepartment of Biology, Eberly College of Science, The Pennsylvania State University, University Park, PA 16802; ^bCenter for Cellular Dynamics, Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA 16802; and ^cCenter for Molecular Investigation of Neurological Disorders, Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, PA 16802

Edited by Kathryn V. Anderson, Sloan-Kettering Institute, New York, NY, and approved November 14, 2016 (received for review July 28, 2016)

Indian Hedgehog (*Ihh*) regulates chondrocyte and osteoblast differentiation through the Glioma-associated oncogene homolog (Gli) transcription factors. Previous *in vitro* studies suggested that Speckle-type POZ protein (Spop), part of the Cullin-3 (Cul3) ubiquitin ligase complex, targets Gli2 and Gli3 for degradation and negatively regulates Hedgehog (Hh) signaling. In this study, we found defects in chondrocyte and osteoblast differentiation in *Spop*-null mutant mice. Strikingly, both the full-length and repressor forms of Gli3, but not Gli2, were up-regulated in *Spop* mutants, and *Ihh* target genes *Patched 1* (*Ptch1*) and parathyroid hormone-like peptide (*Pthlh*) were down-regulated, indicating compromised Hh signaling. Consistent with this finding, reducing Gli3 dosage greatly rescued the *Spop* mutant skeletal defects. We further show that Spop directly targets the Gli3 repressor for ubiquitination and degradation. Finally, we demonstrate in a conditional mutant that loss of *Spop* results in brachydactyly and osteopenia, which can be rescued by reducing the dosage of Gli3. In summary, Spop is an important positive regulator of *Ihh* signaling and skeletal development.

endochondral ossification | Gli3 | ubiquitin ligase | skeletal development | osteoporosis

The human skeleton provides essential mechanical support, mobility, and mineral storage critical for health (1). In development, most bones form through endochondral ossification in which chondrocytes in the growth plate proliferate, undergo hypertrophic differentiation, and secrete calcium-containing extracellular matrix (2). The osteoblasts in the perichondrium, a thin layer of tissue surrounding the cartilage, replace the dying chondrocytes and secrete more bone matrix. On the other hand, osteoclasts, derived from white blood cells, invade and digest bone matrix. The balance between the osteoblast and osteoclast activities allows calcium homeostatic control and bone health. In osteopenia and osteoporosis, conditions afflicting more than 10 million Americans, an abnormal decrease in osteoblast activity or increase in osteoclast activity results in the loss of bone mass (1, 3). Unfortunately, our understanding of these bone diseases has been hindered by incomplete knowledge in the molecular mechanisms underlying endochondral bone development and remodeling.

Indian Hedgehog (*Ihh*), a member of the Hedgehog (Hh) family of signaling proteins, is essential for endochondral bone development (4). *Ihh* regulates gene expression through the Gli family of transcription factors, which act as both transcriptional activators and repressors (5). In the absence of Hh, efficient proteolytic processing turns Gli3 into a transcriptional repressor (Gli3R) whereas processing of Gli2 is rather inefficient (6–8). Hh inhibits Gli processing and converts the full-length Gli proteins into transcriptional activators. Both Gli2 and Gli3 play important roles in the regulation of bone formation downstream of *Ihh* (9–12).

Ihh maintains the expression of parathyroid hormone-like peptide (*Pthlh*) (Mouse Genome Informatics) in the periarticular perichondrium (13), which then stimulates the proliferation and delays the hypertrophic differentiation of chondrocytes, in part through Gli3R (14, 15). *Ihh* also promotes chondrocyte proliferation (13, 16) and hypertrophic differentiation through *Pthlh*-independent mechanisms (17). In addition, *Ihh* signaling

is required in the perichondrium for osteoblast differentiation and bone formation (4, 12).

Speckle-type POZ protein (Spop) is the substrate-recognition subunit of a Cullin-Ring E3 ubiquitin ligase that targets mammalian Gli2 and the full-length form of Gli3 (Gli3FL) for ubiquitination and degradation *in vitro* (18–21). The Spop homolog in *Drosophila*, known as *hib* or *rdx*, also mediates the degradation of Ci, the sole Gli family member in flies, and inhibits Hh signaling (22, 23). Overexpression of Spop in *Xenopus* similarly reduces Hh pathway activation (24). An *Spop* mutant mouse strain was analyzed previously, but defects only in endocrine pancreas were reported (25). Another Speckle-type POZ protein, Spop-like (Spopl), exhibits similar substrate specificity and similar, albeit somewhat weaker, ubiquitination activity as Spop (26). Its *in vivo* biological function has not been studied.

Here, we report that loss of *Spop*, but not *Spopl*, disrupts chondrocyte hypertrophy and osteoblast differentiation in the mouse, suggesting the requirement for Spop-mediated protein degradation in mouse skeletal development. Surprisingly, loss of *Spop* results in an increase in the level of Gli3R and a decrease in *Ihh* signaling. Consistent with this *in vivo* observation, we find that overexpressed Spop targets both Gli3FL and Gli3R for ubiquitination and degradation. Supporting the role of increased Gli3R in *Spop* mutant phenotype, reducing the dosage of Gli3 restores normal *Ihh* signaling and endochondral ossification. Finally, we show that limb mesenchyme-specific loss of *Spop* results in shorter distal limb bones and lower bone density in the adults, which can be rescued by reducing the dosage of Gli3.

Results

Spop, but Not Spopl, Is Required for Normal Skeletal Development.

To determine the requirement for *Spop* in development, we characterized two *Spop* mutant mouse strains (Fig. S1A). The first strain, *Spop*^{tm1a(KOMP)Mbp}, or *Spop*^{lacZKI}, contained a bacterial

Significance

Skeletal diseases place a huge burden on patients and society, and yet their genetic basis remains poorly understood. In this article, we identify Speckle-type POZ protein (Spop) as a regulator of skeletal development, loss of which leads to shorter digit bones and lower bone density. We also show that, in striking contrast to the current dogma positing Spop as a negative regulator of Hedgehog (Hh) signaling, Spop regulates skeletal development by promoting Indian Hedgehog (*Ihh*) signaling. Therefore, our work represents an important conceptual advance in the understanding of *Ihh* signaling and skeletal development and provides a potential new target for the diagnosis and intervention of bone diseases such as osteoporosis.

Author contributions: A.L. designed research; H.C. performed research; H.C. and A.L. analyzed data; and H.C. and A.L. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

¹To whom correspondence should be addressed. Email: axl25@psu.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1612520114/-DCSupplemental.




Fig. 1. *Spop* regulates skeletal development. (A and B) Xgal-stained sections of an E14.5 *Spop^{lacZKI/+}* embryo showing *Spop-lacZ* expression (blue) in the cartilage and perichondrium of the forelimb (A) and in the developing skull (B). (C) Alcian blue- and Alizarin red-stained E17.5 autopods. Arrows, the ossification centers that are diminished in *Spop* mutants. (D) The length of the calcified region of metacarpal 3 and metatarsal 3. $n \geq 3$ embryos per genotype and stage. * $P < 0.05$ (t test).

β -galactosidase (*lacZ*) reporter in the third intron of *Spop*, which was predicted to terminate *Spop* transcription after the third exon. The removal of the fourth and fifth exons of *Spop* in the second strain, *Spop^{ΔEx}*, similarly truncated the *Spop* protein after exon 3 due to a frameshift (Fig. S1A). Both alleles were likely null because the predicted protein products lacked the entire POZ (Cul3-binding) and MATH (substrate-binding) domains (Fig. S1A). We confirmed the absence of *Spop* protein in the homozygotes of both mutant alleles by immunoblot analyses using an *Spop*-specific antibody (Fig. S1B). Homozygous mutant pups of both strains died shortly after birth, similar to a previous report, consistent with the prediction that they are both likely null (25) (Fig. S1C and D and Tables S1–S3). Therefore, we refer to both mutant alleles as *Spop^{-/-}* for brevity.

The *lacZ* reporter in the *Spop^{lacZKI}* allele allowed us to detect the expression pattern of *Spop* with great sensitivity. We found that, starting from embryonic day (E) 12.5, *Spop-lacZ* was expressed at high levels in the developing endochondral skeleton, including the long bones, costal cartilage, ribs, and vertebrae (Fig. 1A and Fig. S2). A closer look revealed *lacZ* expression in the chondrocytes and perichondrium, as well as surrounding mesenchymal cells that are possibly muscle precursors. Robust expression of *Spop* was also present in the primordium of dermal bones (Fig. 1B).

The strong *Spop* expression in the developing cartilage prompted us to examine endochondral ossification in *Spop* mutants. Indeed, we found delayed calcification in the ribs, vertebrae, and long bones in *Spop* mutants at multiple stages (Fig. S3A–D). In particular, the calcification of the metacarpals and metatarsals was severely compromised in *Spop* mutants, with the defects more severe in the hindlimbs (Fig. 1C and D). The enlarged fontanelles and fenestrated dermal bones in *Spop* mutants suggested that intramembranous ossification was also affected in the absence of *Spop* (Fig. S3E and F).

Spopl shares 85% sequence identity with *Spop* and exhibits similar, but weaker, E3 ubiquitin ligase activity than *Spop* (26). To investigate whether *Spop* and *Spopl* play redundant roles in mouse development, we characterized *Spopl* mutants and *Spop*; *Spopl* double mutants. *Spopl* homozygous mutants were viable and fertile with no apparent morphological and skeletal defects, and *Spop*; *Spopl* double mutants exhibited similar skeletal defects to *Spop* mutants (Fig. S4), indicating that *Spopl* did not compensate for the loss of *Spop* in mouse development.

Spop Regulates Hypertrophic Differentiation of Chondrocytes. We next investigated whether the ossification defects in *Spop* mutants resulted from disrupted chondrocyte differentiation. As we expected, the primary ossification center flanked by hypertrophic

chondrocytes was much narrower in the E15.5 *Spop* mutant humerus compared with that of WT (Fig. 2A and A'). Similar, but more severe, defects were observed in E18.5 metatarsals (Fig. 2B and B'). To better evaluate the hypertrophic differentiation of chondrocytes in *Spop* mutants, we examined the expression of genes specific to chondrocytes at various stages of differentiation in the E13.5 humerus. At the transition from proliferation to hypertrophic differentiation, chondrocytes switched from *Col2a1* expression to *Col10a1* expression (Fig. 2C and D). Interestingly, the *Col2a1^{-/-}Col10a1⁺* domain was greatly reduced in *Spop* mutants, suggesting that hypertrophic differentiation was defective (Fig. 2C' and D'). In addition, the two narrow domains of *Pth1r* and *Ihh* expression in the prehypertrophic chondrocytes separated by the hypertrophic zones were much closer to each other in *Spop* mutants, confirming the hypertrophic differentiation defects (Fig. 2E–F').

Spop Promotes Bone Formation and Osteoblast Differentiation. The expression of *Spop* in the perichondrium, where osteoblasts are derived (Fig. 1A), suggests that *Spop* may be important for bone formation and osteoblast differentiation. Indeed, the bone collar present in E18.5 WT metatarsal 3 was absent in *Spop* mutants (Fig. 2B and B'). A von Kossa assay confirmed that the bone collar was similarly absent from the region next to the prehypertrophic chondrocytes of the *Spop* mutant humerus at E15.5 (Fig. 3A and A'). We also found that the inner layer of the perichondrium in *Spop* mutants failed to properly differentiate into cuboidal osteoblasts and that the perichondrium was thicker




Fig. 2. Loss of *Spop* disrupts hypertrophic differentiation of chondrocytes. (A–B) H&E-stained longitudinal sections of humeri and metatarsal 3. H, hypertrophic zone; OC, primary ossification center; P, proliferating zone. Arrows, bone collar. (C–G') RNA in situ hybridization (purple) on longitudinal sections of E13.5 humeri. (C–D) Hypertrophic chondrocytes (bracket) express *Col10a1*, but not *Col2a1*. (E–F) *Pth1r* and *Ihh* are expressed in prehypertrophic chondrocytes (bracket). (G and G') *Pthlh* is expressed in periarticular perichondrium. Hu, humerus; Ul, ulna. $n \geq 3$ embryos per genotype were analyzed for all experiments.




Fig. 3. Loss of *Spop* impairs bone formation and osteoblast differentiation. (A and A') Von Kossa-stained longitudinal sections of E15.5 humerus. (Insets) The perichondrium (brackets) by the prehypertrophic zone. The orthotropic bone collar (arrowheads) is missing in *Spop* mutant. (B and B') H&E-stained sections showing the perichondrium (between the green dashed lines) by the prehypertrophic zone of E15.5 proximal humerus. Arrowheads, cuboidal osteoblasts. H, hypertrophic zone; P, proliferating zone. (C–E) RNA in situ hybridization of *Runx2*, *Bmp2*, and *Bglap*. (F–H) qRT-PCR analyses of *Col1a1*, *Sp7*, *Acp5*, and *Ctsk* in *Spop*-null (F and G), *Spop*^{cKO} (H), and control samples. * $P < 0.05$; ns, $P > 0.05$ (t test). $n \geq 3$ embryos per genotype were analyzed for all experiments.

than that in control littermates (Fig. 3 B and B'). Furthermore, *Runx2* and *Bmp2*, markers for the precursors and mature osteoblasts, respectively, were both down-regulated in the *Spop* mutant metacarpals (Fig. 3 C–D'). Of note, chondrocytes in the metacarpals did not undergo hypertrophic differentiation until E15.5, suggesting that the lack of *Runx2* expression was not secondary to the defects in chondrocyte hypertrophy. Similarly, the expression of *Bglap*, also known as *Osteocalcin*, a marker of terminally differentiated osteoblasts, was reduced in *Spop* mutants (Fig. 3 E and E'). Finally, we used quantitative reverse transcription PCR (qRT-PCR) to measure the expression levels of *Col1a1*, a major extracellular matrix protein produced by osteoblast, and *Sp7/osterix*, a transcription factor required for osteoblast maturation, and found that both genes were significantly down-regulated at E13.5 in the *Spop* mutant forelimbs (Fig. 3 F). These results suggest that *Spop* promotes bone formation, likely by cell-autonomously promoting osteoblast differentiation.

Decreased Ihh Signaling and Gli3R Accumulation in *Spop* Mutants. Previous in vitro studies found that *Spop* inhibited Hh signaling by targeting Gli2 and Gli3FL for degradation (18–21, 23). To test whether Ihh signaling was affected by the loss of *Spop*, we examined the expression of *Patched 1* (*Ptch1*), a direct transcriptional target of Ihh, in E13.5 forelimbs. Interestingly, we found a significant reduction in *Ptch1* expression in E13.5 *Spop* mutant forelimbs through qRT-PCR, indicating an unexpected positive role of *Spop* in Ihh signaling (Fig. 4A). Moreover, both RNA in

situ hybridization with a *Ptch1* probe (Fig. 4B) and a *Ptch1-lacZ* reporter (Fig. S5 A–B') showed a reduction of *Ptch1* expression in the chondrocytes and perichondrium of *Spop* mutants, suggesting that *Spop* regulates bone formation by promoting Ihh signaling. In contrast, *Ptch1-lacZ* expression in the posterior part of E12.5 *Spop* mutant limb buds was indistinguishable from that of the littermates (Fig. S5 C and C'), suggesting that loss of *Spop* has no obvious effect on Sonic Hedgehog signaling from the zone of polarizing activity. Consistent with decreased Ihh signaling, qRT-PCR revealed that the expression of *Pthlh*, another target gene of Ihh signaling, was also significantly reduced (Fig. 4A), although this moderate reduction was not obvious through RNA in situ hybridization (Fig. 2 G and G'). These results suggest that *Spop* promotes endochondral ossification by positively regulating Ihh signaling.

To understand the molecular basis of this positive role of *Spop* in Ihh signaling, we examined the levels of Gli2 and Gli3 in E13.5 forelimbs by immunoblot analyses. Despite previous in vitro data suggesting an important role of *Spop* in Gli2 degradation (18–21, 23), the level of Gli2 was not significantly changed in *Spop* mutants (Fig. 4C). In contrast, the levels of both Gli3FL and Gli3R in the *Spop* mutant forelimbs were more than twice those in WT (Fig. 4C). Because Gli3R was known to antagonize Ihh signaling in endochondral ossification (10), we conclude that *Spop* promotes Ihh signaling in skeletal development by down-regulating Gli3R.




Fig. 4. Increased Gli3 repressor and compromised Ihh signaling in *Spop* mutants. (A) qRT-PCR analyses of *Ptch1* and *Pthlh* in E13.5 forelimbs. (B) RNA in situ hybridization of *Ptch1* on E13.5 forelimb sections. (C) Immunoblots of E13.5 forelimbs with Gli2, Gli3, and β -tubulin antibodies. * $P < 0.05$; ns, $P > 0.05$ (t test). (D) Immunoblots of *Spop*, Gli3, and Gli3¹⁻⁷⁰⁰ with Myc-GFP as a transfection control. *, a nonspecific band. (E) In vivo ubiquitination assay of Gli3 and Gli3¹⁻⁷⁰⁰. HEK 293T cells were treated with MG132 for 8 h before immunoprecipitation (IP) and immunoblot analyses. *, a nonspecific band. (A–C) $n = 3$ embryos per genotype were analyzed. (D and E) $n = 3$ independent experiments were performed.




Fig. 5. Increased Gli3 repressor underlies the ossification defects of *Spop* mutants. (A) Immunoblots of Gli3 and β -tubulin on E17.5 metacarpals. (B) Alcian blue- and Alizarin red-stained postnatal day 0 (P0) autopods. Arrows, the ossification centers. (C) H&E-stained E17.5 metacarpal 3. Brackets, the hypertrophic zone. $n = 3$ embryos per genotype were analyzed.

Because the levels of both Gli3FL and Gli3R were higher in *Spop* mutants, it was possible that Spop targeted exclusively Gli3FL, which, in turn, generated Gli3R through proteolytic processing. Alternatively, because previous studies showed interaction between Spop and the N terminus of Gli3 (19, 20), Spop may interact and directly target Gli3R for degradation. To test the latter possibility, we first examined the physical interaction between Spop and Gli3¹⁻⁷⁰⁰, a truncated form mimicking Gli3R, by coexpressing FLAG-Spop with GFP-tagged Gli3, Gli3¹⁻⁷⁰⁰, and Gli2, respectively, and immunoprecipitating FLAG-Spop. We found that, similar to Gli3 and Gli2, Gli3¹⁻⁷⁰⁰ coprecipitated with Spop (Fig. S6B). As a negative control, Gli2^{5m}, a Gli2 variant with mutated Spop-binding motifs, did not coprecipitate with Spop (19) (Fig. S6B). Reverse immunoprecipitation confirmed that GFP-Spop coprecipitated with FLAG-tagged Gli3 and Gli3¹⁻⁷⁰⁰ (Fig. S6C). Subsequently, we tested the ability of Spop to reduce the level of Gli3R in cultured cells. We found that coexpressing Spop in HEK 293T cells reduced the levels of both Gli3 and Gli3¹⁻⁷⁰⁰ (Fig. 4D and Fig. S6A). Finally, we found that overexpressed Spop promoted the ubiquitination of both Gli3 and Gli3¹⁻⁷⁰⁰ in HEK 293T cells (Fig. 4E and Fig. S6D). These results indicated that Gli3R was a direct target of Spop and that the increase in Gli3R in *Spop* mutants resulted at least partially from lack of Spop-mediated degradation.

The Increase in Gli3R Underlies the Ossification Defects in *Spop* Mutants. To test the hypothesis that the increase in the level of Gli3R and decreased *Ihh* signaling underlie the skeletal defects in *Spop*-null mutants, we generated *Spop*^{-/-};*Gli3*^{+/-} double mutants in which Gli3FL and Gli3R were restored to near WT level (Fig. 5A). Importantly, both the endochondral ossification and chondrocyte hypertrophy were restored in metacarpals and metatarsals in *Spop*^{-/-};*Gli3*^{+/-} double mutants (Fig. 5B and C).

Consistent with our observation that the levels of Gli3, but not Gli2, were altered in *Spop* mutant limbs, *Spop*;*Gli2* double homozygous mutants exhibited ossification defects (Fig. S7A), failure in bone matrix deposition (Fig. S7B), and hypertrophic differentiation (Fig. S7C) in digit bones at E17.5, similar to *Spop* single mutants. In contrast, loss of *Spop* had no effect on either digit formation or the ossification of the metacarpals and metatarsals in the absence of Gli3 (Fig. S7D). The calcification (Fig. S7E) and hypertrophic differentiation (Fig. S7F) were also comparable in *Spop*;*Gli3* double homozygous mutants and *Gli3* mutants. These results suggest that Spop regulates endochondral bone development mainly through Gli3, but not Gli2.

Defective Chondrocyte Hypertrophy Results in Brachydactyly in *Spop* Mutants. Because the neonatal lethality of *Spop*-null mutants prevented us from assessing skeletal defects in adults, we generated a limb-specific *Spop* mutant allele (*Spop*^{ckO}) by removing *Spop* in *Prx1*-expressing limb mesenchymal cells. We found that the metacarpals, metatarsals, and phalanges, but not long bones in more proximal parts of the limbs, were significantly shorter in adult *Spop*^{ckO} mutants than in their littermates (Fig. 6A and B).

Therefore, *Spop*^{ckO} can serve as a model for brachydactyly, a common but poorly understood congenital anomaly (27).

We sought to determine whether changes in cell proliferation and/or apoptosis contribute to the short digits in *Spop* mutants at E17.5, when the *Spop* mutant metatarsals were obviously shorter than WT (Fig. S8A). Interestingly, the cell number in *Spop* mutant metatarsals was similar to that in WT littermates (Fig. S8B), suggesting that the shorter metatarsals did not result from a reduction in cell number. In line with this observation, the numbers of proliferating (Ki67⁺) and apoptotic (cleaved caspase 3⁺) cells were also comparable between *Spop* mutant and WT metatarsals (Fig. S8D and E). On the other hand, although large hypertrophic chondrocytes were present in the center of the WT metatarsals, cells were more densely packed throughout the *Spop* mutant metatarsals (Fig. S8B and C). These results suggest that compromised hypertrophic differentiation of chondrocytes underlies the brachydactyly in *Spop* mutants.

Osteoblast Differentiation Defect Results in Osteopenia in *Spop* Mutants. Although the stylopod and zeugopod bones were not shorter in *Spop*^{ckO} mutants, these bones nevertheless exhibit structural defects. Our histological analyses of the femurs showed an obvious reduction in the density of bone matrix in both the primary and secondary ossification centers, as well as thinner bone spicules, in adult *Spop*^{ckO} mutants (Fig. 6C). To further investigate the structural defects of the bones of *Spop*^{ckO} mutants, we evaluated the femurs with X-ray micro-computed tomography (μ CT). The 3D reconstruction of distal metaphysis showed an obvious reduction in trabecular bone density in *Spop*^{ckO} mutants (Fig. 6D), which was confirmed by quantitative analyses of the μ CT data that indicated a significant reduction in bone volume fraction, trabecular number, trabecular thickness, and connectivity density, as well as a significant increase in the specific bone surface and trabecular separation in *Spop*^{ckO} mutants (Fig. S9).

In development and adulthood, bones undergo constant remodeling with osteoblasts producing bone matrix and osteoclasts resorbing it (28). To determine the mechanism underlying the loss of bone mass in *Spop*^{ckO} mutants, we analyzed the expression of osteoblast and osteoclast markers by qRT-PCR. Similar to earlier stages, the expression of both *Col1a1* and *Sp7* was compromised in E17.5 *Spop* mutant femurs, suggesting continued defects in osteoblast differentiation (Fig. 3G). In contrast, the expression of *Acp5* and *Ctsk*, both encoding enzymes secreted by osteoclasts to remodel the bone matrix, was not significantly changed in E17.5 and postnatal day 10 (P10) *Spop* mutants




Fig. 6. Tissue-specific ablation of Spop leads to brachydactyly and osteopenia. (A) Alcian blue- and Alizarin red-stained 5-mo-old hindlimb autopods. Arrows, metatarsal 3. (B) Quantification of 5-wk-old limb bone length. * $P < 0.05$; ** $P < 0.01$; ns, $P > 0.05$ (t test). (C) H&E-stained sections of 5-wk-old distal femur. 1^o, primary ossification center; the areas inside the rectangles are shown in the close-up view. 2^o, secondary ossification center. (D) A 3D reconstruction of the μ CT images of the trabecular bone in 10-wk-old distal metaphysis of femurs. Voxel size, 15 μ m. $n = 3$ males and 3 females per genotype were analyzed.

(Fig. 3 *G* and *H*), suggesting that the loss of bone mass was not the result of too much osteoclast activity. Therefore, osteopenia in *Spop*^{CKO} mutants was likely the result of impaired osteoblast function.

Gli3R Dosage Reduction Rescues Brachydactyly and Osteopenia. Because the increase in Gli3R underlies the defects in chondrocyte and osteoblast differentiation in *Spop*-null mutants, we hypothesized that it also accounted for the osteopenia and brachydactyly in *Spop*^{CKO} mutant mice. To test this hypothesis, we reduced the dosage of Gli3R by generating *Spop*^{CKO};*Gli3*^{+/-} double mutants. We found that the length of metacarpals, phalanges and metatarsals in 2-wk-old *Spop*^{CKO};*Gli3*^{+/-} pups was comparable with that in *Spop*^{flax/flax} littermates, and significantly longer than that in *Spop*^{CKO} mutant littermates (Fig. S10*A*). In addition, both the bone density and thickness of bone spicules increased in *Spop*^{CKO};*Gli3*^{+/-} than in *Spop*^{CKO} mutant femur (Fig. S10*B*). Therefore, we conclude that dysregulation of Gli3R underlies both brachydactyly and osteopenia in *Spop*^{CKO} mutant mice.

Discussion

In the present study, we characterized two null alleles and a limb-specific conditional mutant allele of *Spop* and discovered critical roles for *Spop* in skeletal development and remodeling. We show that chondrocyte and osteoblast differentiation is defective in the absence of *Spop*. Gli3R, but not Gli2, is increased in *Spop* mutants, and *Ihh* signaling is compromised as a result. Finally, we show that limb-specific loss of *Spop* leads to brachydactyly and osteopenia, which can be rescued by reducing the dosage of Gli3R, suggesting that *Spop* could be a new target of intervention for these human disease conditions (Fig. S10 *C* and *D*).

Our finding that *Spop* plays a positive role in *Ihh* signaling is in striking contrast to previous studies suggesting a negative role of *Spop* in *Hh* signaling. In *Drosophila*, loss of *hib/rdx* results in the accumulation of Ci and excess activation of *Hh* signaling (22, 23). Interestingly, expression of *hib/rdx* was found only in cells with high levels of *Hh* pathway activation, in which proteolytic processing of Ci was inhibited. Therefore, the excess activation of *Hh* signaling in *hib/rdx* mutants likely resulted from the accumulation of full-length activated Ci. In contrast, our data and a previous study suggest that the expression of mammalian *Spop* is not limited to cells with active *Hh* signaling (18). Therefore, the accumulation of Gli3R in cells with moderate levels of *Hh* signaling likely accounts for the unique reduction of *Hh* pathway activation in *Spop* mutant mice. Consistent with this hypothesis, overexpression of *hib/rdx* in areas of *Drosophila* wing disk with moderate *Hh* pathway activation resulted in the decrease in both full-length and processed Ci (22).

Recent studies using cultured mammalian cells or mRNA injection in *Xenopus* eggs also suggested a negative role of *Spop* in *Hh* signaling (18–21, 24). It is worth noting that a key difference between these studies and our in vivo data lies in the roles of *Spop* in the regulation of Gli2, the primary activator of the mammalian *Hh* pathway. In these gain-of-function studies, overexpressed *Spop* interacts with Gli2 and targets it for degradation, an observation we confirmed in our own in vitro analysis (Fig. S6*B*). In contrast, we find no significant change in Gli2 protein level in *Spop*-null mutants. Although both Gli3FL and Gli3R accumulate in *Spop* mutants, the increase in Gli3R clearly has more impact on the *Ihh* signaling output, consistent with a previous study indicating an important role of Gli3R in *Ihh* signaling and endochondral ossification (10).

It is not clear why the level of Gli2 is not altered by the loss of *Spop* in vivo. One possible explanation is that *Spop* specifically targets the activated, labile form of Gli2 that exists in only a small number of cells with the highest level of *Hh* pathway activation as suggested by previous in vitro studies (18, 20, 21). Another possibility is that *Spop* does not target Gli2 for degradation under physiological condition. The finding that *Spop* interacts with both the N- and C-terminal regions of Gli3, but only

with the C-terminal region of Gli2, suggests that Gli3 may be a better *Spop* substrate than Gli2 (19, 20).

Previous studies found that Sufu interferes with *Spop*/Gli-interaction and *Spop*-mediated Gli degradation (18, 20, 21), suggesting that *Spop* may specifically target activated Gli proteins that are not associated with Sufu. However, because Sufu is essential for the proteolytic processing of the Gli3 protein (20), the increase in both Gli3FL and Gli3R in *Spop*-null mutants seems to indicate that *Spop* can target nonactivated, Sufu-bound Gli3 for degradation as well. This result could also explain the difference between our results and a recent study suggesting that reducing *Spop* did not affect Gli3R level in cultured cells treated with Shh (21). In fact, figure 4*G* of ref. 21 appeared to show a small and insignificant increase in the levels of both Gli3FL and Gli3R with the reduction of *Spop* in the absence of Shh, consistent with our finding.

Our findings that *Spop* interacts with Gli3R and regulates its ubiquitination and degradation is consistent with previous reports of direct interaction between the N terminus of Gli3 and *Spop* (19, 20). A recent study further revealed multiple ubiquitination sites on the N terminus of Gli3 that are sufficient for *Spop*-catalyzed ubiquitination (29). However, our data seem to be at odds with a recent study showing no effect of *Spop* overexpression on the stability of Gli3¹⁻⁷⁰⁰ in C3H10T1/2 cells (20). This difference could result from the use of different antibodies for immunoblots. In ref. 20, a Gli3 antibody was used to detect both the endogenous Gli3R and overexpressed Gli3¹⁻⁷⁰⁰. Because endogenous Gli3R is hardly affected by *Spop* overexpression due to the low transfection efficiency, a moderate decrease in Gli3¹⁻⁷⁰⁰, which comigrates with endogenous Gli3R, may be difficult to detect. It is also possible that the expression levels of *Spop* in C3H10T1/2 and HEK 293T cells underlie the different effects on Gli3¹⁻⁷⁰⁰ degradation because we have failed to express *Spop* at sufficient levels in C3H10T1/2 cells in an attempt to repeat the experiment described in ref. 20.

In addition to Gli proteins, *Spop* mediates the ubiquitination of at least 20 more proteins through serine/threonine-rich degrons (19, 30). Therefore, it is theoretically possible that changes in the activities of other *Spop* substrates may also contribute to the skeletal defects observed in *Spop* mutants. However, the near-complete rescue of bone and cartilage development in *Spop*^{-/-};*Gli3*^{+/-} and *Spop*^{CKO};*Gli3*^{+/-} double mutants suggests that *Spop*-mediated ubiquitination of other substrates plays minimal roles in this process at best. Nevertheless, we failed to recover *Spop*^{-/-};*Gli3*^{+/-} double mutants at weaning, suggesting that the increase in the level of Gli3 does not account for the lethality of *Spop*-null mutants.

In conclusion, we provide here solid evidence for essential roles of *Spop*-mediated ubiquitination in chondrocyte and osteoblast differentiation during skeletal development, and normal bone size and density in adult. Importantly, we reveal a surprisingly positive function of *Spop* in *Ihh* signaling through specific down-regulation of Gli3, particularly its repressor form. Clinically, this knowledge allows us to better understand the pathology and potential intervention of skeletal disorders such as brachydactyly and osteoporosis.

Materials and Methods

Animal Husbandry. *Spop*^{tm1a(KOMP)Mbp} and *Spop*^{tm1(KOMP)Vlcr} mice were purchased from the Knockout Mouse Project (KOMP) and were genotyped per KOMP's instruction (<https://www.komp.org/>). Other mouse strains used in this study are *Gli2*^{tm2.1Alj} (31), *Gli3*^{T⁺X⁻J} (32), *Tg(Ella-Cre)C5379Lmgd/J* (33), *Tg(Prrx1-cre)1Cjt* (34), and *Ptch1*^{tm2Mps} (35). The use of animals in this study was approved by the Institutional Animal Care and Use Committee at the Pennsylvania State University.

Cell Culture, Transfection, and Biochemical Analyses. HEK 293T cells were cultured in DMEM (Cellgro) supplemented with 10% (vol/vol) FBS (Thermo Fisher) and transfected with polyethylenimine (PEI) (Polysciences). Immunoblot analyses were performed with IRDye-680RD and 800CW-conjugated secondary antibodies following the manufacturer's instructions and were quantified with Image Studio (LI-COR). Immunoprecipitation was performed with a FLAG-IP kit (Sigma-Aldrich) following the manufacturer's instructions.

For the ubiquitination assay, cells were serum-starved for 40 h, treated with 50 μ M MG132 (Sigma-Aldrich) for 8 h before harvesting, lysed as previously described (23) with sonication, and subjected to FLAG immunoprecipitation. Antibodies used in these assays are listed in *SI Materials and Methods*.

Quantitative Reverse Transcriptase Real-Time PCR. Tissues were dissected, and postnatal bones were freed of muscle and marrow and pulverized in liquid nitrogen. RNA isolation was performed using a NucleoSpin RNA kit (Macherey-Nagel). Then, 1 μ g of RNA was used for reverse transcription with qScript cDNA SuperMix (Quanta Biosciences). PCR was performed in a StepOne Plus Real-time PCR system (Applied Biosystems) with SYBR green (Quanta Biosciences). Primer sequences for qRT-PCR are listed in *SI Materials and Methods*.

RNA in Situ Hybridization. RNA in situ hybridization was performed on cryosections with digoxigenin (DIG)-labeled antisense probes and BM purple (Sigma Aldrich) as substrate and counterstained with Nuclear Fast Red (Sigma-Aldrich) according to a previously published protocol (36).

Histology and Immunohistochemistry. Bone tissues were decalcified in PBS/14% (wt/vol) EDTA (pH 7) before being embedded in paraffin. H&E staining was performed with a Gemini ES Automated Slide Stainer (Thermo) loaded with SelecTech hematoxylin and eosin staining system (Leica). For von Kossa assay, undecalcified sections were stained with 1% silver nitrate and counterstained with hematoxylin.

For immunohistochemistry, paraffin sections were deparaffinized and rehydrated. Antigen retrieval was performed by heating the sections in 10 mM citrate buffer (pH 6.0) at 95 $^{\circ}$ C for 10 min. The sections were then blocked with 1% goat serum and subjected to primary and HRP-conjugated

secondary antibody incubation. Finally, color was developed with 3,3'-diaminobenzidine (DAB) (Ni) and hydrogen peroxide, and sections were lightly counterstained with hematoxylin. Antibodies used in these assays are listed in *SI Materials and Methods*.

Micro-Computed Tomography. For 3D bone analysis, femurs from 10-wk-old mice were scanned in a Scanco μ CT40 Desktop MicroCT Scanner (SCANCO Medical AG) with air as the medium. Images were acquired with the setting of 55 kVp, 145 μ A, and 200 ms integration time. Images were reconstructed and stored in 3D arrays with an isotropic voxel size of 15 μ m. Then, 100 slices at distal metaphysis were selected 750 μ m from the proximal end of the distal growth plate for trabecular analysis. Company-provided software and custom scripts were used to view images, create 3D models of the bones and determine bone volume and other parameters.

ACKNOWLEDGMENTS. We thank Drs. Andrea Mastro, Philip Reno, and Yingwei Mao for critically reading this manuscript; Drs. Lee Niswander (University of Colorado), Matthew Hilton (Duke University), Henry Kronenberg (Harvard Medical School), Patricia Ducy (Columbia University), Jin Jiang (University of Texas Southwestern Medical Center), Matt Scott (Carnegie Institute), Alex Joyner (Sloan-Kettering Institute), Pao-tien Chuang (University of California, San Francisco), Edward Yeh (University of Texas MD Anderson Cancer Center), and Bernard Luscher and Yingwei Mao (Pennsylvania State University) for sharing reagents; Dr. Neil Sharkey and Noriaki Okita for great help in acquiring and analyzing the μ CT data; and the Microscopy and Cytometry Facility and Genomics Core Facility of Pennsylvania State University for technical support. This work was supported by NIH Grant HD083625, a Pennsylvania State University Start-up Fund (to A.L.), and a J. Lloyd Huck Dissertation Research Grant (to H.C.).

1. USHHS (2004) *Bone Health and Osteoporosis: A Report of the Surgeon General* (US Department of Health and Human Services OostSG, Rockville, MD).
2. Mackie EJ, Tatarczuch L, Mirams M (2011) The skeleton: A multi-functional complex organ: The growth plate chondrocyte and endochondral ossification. *J Endocrinol* 211(2):109–121.
3. Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: Now and the future. *Lancet* 377(9773):1276–1287.
4. St-Jacques B, Hammerschmidt M, McMahon AP (1999) Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. *Genes Dev* 13(16):2072–2086.
5. Ye X, Liu A (2011) Hedgehog signaling: Mechanism and evolution. *Front Biol* 6(6):504–521.
6. Pan Y, Wang B (2007) A novel protein-processing domain in Gli2 and Gli3 differentially blocks complete protein degradation by the proteasome. *J Biol Chem* 282(15):10846–10852.
7. Wang B, Fallon JF, Beachy PA (2000) Hedgehog-regulated processing of Gli3 produces an anterior/posterior repressor gradient in the developing vertebrate limb. *Cell* 100(4):423–434.
8. Pan Y, Bai CB, Joyner AL, Wang B (2006) Sonic hedgehog signaling regulates Gli2 transcriptional activity by suppressing its processing and degradation. *Mol Cell Biol* 26(9):3365–3377.
9. Miao D, et al. (2004) Impaired endochondral bone development and osteopenia in Gli2-deficient mice. *Exp Cell Res* 294(1):210–222.
10. Hilton MJ, Tu X, Cook J, Hu H, Long F (2005) Ihh controls cartilage development by antagonizing Gli3, but requires additional effectors to regulate osteoblast and vascular development. *Development* 132(19):4339–4351.
11. Joeng KS, Long F (2009) The Gli2 transcriptional activator is a crucial effector for Ihh signaling in osteoblast development and cartilage vascularization. *Development* 136(24):4177–4185.
12. Long F, et al. (2004) Ihh signaling is directly required for the osteoblast lineage in the endochondral skeleton. *Development* 131(6):1309–1318.
13. Karp SJ, et al. (2000) Indian hedgehog coordinates endochondral bone growth and morphogenesis via parathyroid hormone related-protein-dependent and -independent pathways. *Development* 127(3):543–548.
14. Mau E, et al. (2007) PTHrP regulates growth plate chondrocyte differentiation and proliferation in a Gli3 dependent manner utilizing hedgehog ligand dependent and independent mechanisms. *Dev Biol* 305(1):28–39.
15. Hsu SH, et al. (2012) Suppressor of fused (Sufu) mediates the effect of parathyroid hormone-like hormone (Pthlh) on chondrocyte differentiation in the growth plate. *J Biol Chem* 287(43):36222–36228.
16. Long F, Zhang XM, Karp S, Yang Y, McMahon AP (2001) Genetic manipulation of hedgehog signaling in the endochondral skeleton reveals a direct role in the regulation of chondrocyte proliferation. *Development* 128(24):5099–5108.
17. Mak KK, Kronenberg HM, Chuang PT, Mackem S, Yang Y (2008) Indian hedgehog signals independently of PTHrP to promote chondrocyte hypertrophy. *Development* 135(11):1947–1956.
18. Chen MH, et al. (2009) Cilium-independent regulation of Gli protein function by Sufu in Hedgehog signaling is evolutionarily conserved. *Genes Dev* 23(16):1910–1928.
19. Zhang Q, et al. (2009) Multiple Ser/Thr-rich degrons mediate the degradation of Ci/Gli by the Cul3-HIB/SPOP E3 ubiquitin ligase. *Proc Natl Acad Sci USA* 106(50):21191–21196.
20. Wang C, Pan Y, Wang B (2010) Suppressor of fused and Spop regulate the stability, processing and function of Gli2 and Gli3 full-length activators but not their repressors. *Development* 137(12):2001–2009.
21. Wen X, et al. (2010) Kinetics of hedgehog-dependent full-length Gli3 accumulation in primary cilia and subsequent degradation. *Mol Cell Biol* 30(8):1910–1922.
22. Kent D, Bush EW, Hooper JE (2006) Roadkill attenuates Hedgehog responses through degradation of Cubitus interruptus. *Development* 133(10):2001–2010.
23. Zhang Q, et al. (2006) A hedgehog-induced BTB protein modulates hedgehog signaling by degrading Ci/Gli transcription factor. *Dev Cell* 10(6):719–729.
24. Schwend T, et al. (2013) Stabilization of speckle-type POZ protein (Spop) by Daz interacting protein 1 (Dzip1) is essential for Gli turnover and the proper output of Hedgehog signaling. *J Biol Chem* 288(45):32809–32820.
25. Claiborn KC, et al. (2010) Pcf11 modulates Pdx1 protein stability and pancreatic beta cell function and survival in mice. *J Clin Invest* 120(10):3713–3721.
26. Errington WJ, et al. (2012) Adaptor protein self-assembly drives the control of a cullin-RING ubiquitin ligase. *Structure* 20(7):1141–1153.
27. Temtamy SA, Aglan MS (2008) Brachydactyly. *Orphanet J Rare Dis* 3:15.
28. Long F (2012) Building strong bones: Molecular regulation of the osteoblast lineage. *Nat Rev Mol Cell Biol* 13(1):27–38.
29. Pierce WK, et al. (2016) Multiple weak linear motifs enhance recruitment and processivity in SPOP-mediated substrate ubiquitination. *J Mol Biol* 428(6):1256–1271.
30. Zhuang M, et al. (2009) Structures of SPOP-substrate complexes: Insights into molecular architectures of BTB-Cul3 ubiquitin ligases. *Mol Cell* 36(1):39–50.
31. Bai CB, Joyner AL (2001) Gli1 can rescue the in vivo function of Gli2. *Development* 128(24):5161–5172.
32. Buscher D, Grotevold L, Ruther U (1998) The XtJ allele generates a Gli3 fusion transcript. *Mamm Genome* 9(8):676–678.
33. Lakso M, et al. (1996) Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. *Proc Natl Acad Sci USA* 93(12):5860–5865.
34. Logan M, et al. (2002) Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. *Genesis* 33(2):77–80.
35. Oro AE, Higgins K (2003) Hair cycle regulation of Hedgehog signal reception. *Dev Biol* 255(2):238–248.
36. Liu J, Liu A (2014) Immunohistochemistry and RNA in situ hybridization in mouse brain development. *Methods Mol Biol* 1082:269–283.